C2N Diagnostics

EARLIER DETECTION, PROVEN ACCURACY.   A new Journal of Alzheimer's Disease publication highlights new modeling data demonstrating that use of the PrecivityAD2® blood test with a cognitive assessment in primary care could (potentially) reduce wait times for specialist referrals by 35%, from 23 to 15 months.   Earlier detection could help clinicians accelerate evaluation pathways—reducing delays and giving patients and families the clarity they need sooner.   Powered by mass spectrometry, C2N continues advancing Alzheimer’s blood testing.   For more details, see the full article https://lnkd.in/eNwFbvYT   

Researchers in the United Kingdom are using the PrecivityAD2® blood test to prepare for the future acceleration of diagnosis and clinical decision-making in either primary care or for patients waiting to see dementia specialists. The collaboration is occurring through C2N’s partnership with the Davos Alzheimer's Collaborative (DAC). DAC’s Healthcare System Preparedness program has started the Accurate Dx program. Imperial College London is the only United Kingdom center. The study is designed around testing the accuracy of PrecivityAD2® in primary care pathways for dementia diagnosis, placing this new technological approach directly within primary care research sites, rather than in hospital or specialist settings, for a quicker and more accurate diagnosis early in disease stages. https://lnkd.in/ehmH8n4r #Alzheimers #UnitedKingdom #NHSAlzheimers

ACCURACY MATTERS.   ·       Analytical accuracy is becoming a critical differentiator in Alzheimer’s blood testing. In other words, does a test measure what it says it is measuring? As blood biomarker testing evolves toward disease detection at its earliest stages, the technology used to measure these biomarkers of brain pathology matters. C2N’s LC‑MS/MS‑based %p‑tau217 assay delivers the rugged analytical accuracy needed to detect subtle biological changes with confidence. ·       A new research study of 982 community-dwelling, cognitively unimpaired adults followed for 12 years showed that baseline %p‑tau217 levels measured with C2N’s LC‑MS/MS assay strongly predicted long‑term cognitive decline, neurodegeneration, and progression to MCI/dementia. The assay also stratified individuals by future risk, distinguishing those with lower versus higher likelihood of cognitive decline over time. ·       Published this week in Alzheimer’s & Dementia, the study also found that C2N’s LC‑MS/MS‑based %p‑tau217 assay outperformed p‑tau217 immunoassays in predicting long‑term cognitive outcomes.  ·       Powered by mass spectrometry, C2N continues showing what is possible in Alzheimer’s blood testing through analytical accuracy and performance. See “Prognostic value of plasma %p-tau217 in cognitively unimpaired older adults” for more details.   Congratulations to the co-authors and all the CIEN Foundation investigators for this impactful work!     Read the full manuscript in Alzheimer’s & Dementia here: https://lnkd.in/eUyHDHdJ #AlzheimersDisease #Alzheimers #diagnostictest

AAIC 2026 showcased the remarkable pace of innovation in Alzheimer’s disease and C2N Diagnostics is proud to be at the forefront!   Thank you to the investigators, clinicians, collaborators, customers, and partners who made this year’s meeting such a success. The conversations, science, and a shared commitment to patients continue to move the field forward.   We’re excited about what’s ahead and look forward to building on this momentum with more significant milestones in the weeks to come. #AAIC2026 #Alzheimers #BloodBiomarkers #PrecisionMedicine #Diagnostics #BrainHealth #Innovation #C2NDiagnostics

C2N Diagnostics, LLC, a pioneer in advanced brain health diagnostics, is adding to its evidence-based legacy at the Alzheimer’s Association International Conference 2026 in London, July 12-15. 12 sessions and 15 posters will offer novel insights relating to the Precivity™ blood tests. These presentations/posters include: Wednesday, July 15 8:23 – 8:30 am Plasma MTBR-tau243 Identifies Chronic Traumatic Encephalopathy as Well as Alzheimer’s Disease* Location: S11 2:22 – 2:32 pm Using Blood Biomarkers and Protein Signatures in Alzheimer’s Treatment Clinic to Predict Treatment Response and ARIA Location: Victoria 5/6 2:32 – 2:42 pm Concurrent Longitudinal Associations Between Plasma p-tau217, PET Imaging, and Cognition in ADNI And HABS-HD Cohorts Location: Victoria 1/4 Poster (Exhibit Hall) Wednesday, July 15 #0399 Predicting Onset of Alzheimer Disease Symptoms with the interaction of Plasma %p-tau217 and Age Combined with Brain Volumes #AAIC #AAIC26 #AAIC2026

Exciting results on clinical decision-making using the PrecivityAD2™ blood test.

Can an Alzheimer's disease blood test change real-world clinical decision-making? New real-world data presented by Sebastian Palmqvist on behalf of the The Swedish BioFINDER study investigators at AAIC 2026 suggests that the answer is yes. In a Swedish study of 1,356 patients evaluated for cognitive impairment across primary care and memory clinics, use of the PrecivityAD2® blood test and Amyloid Probability Score 2 (APS2) changed clinical management in more than 60% of patients. The study also increased physicians' diagnostic confidence. Primary care physicians’ diagnostic accuracy for Alzheimer’s disease improved from 62% before testing to 88% after testing, performing similarly to dementia specialists. As many patients begin their diagnostic journey in primary care, where access to PET imaging, CSF testing, and dementia specialists may be limited, these findings add to the growing evidence that blood biomarkers can provide clinically meaningful information that influences real-world patient management. Congratulations to the investigators on this important contribution, and we look forward to the discussion at AAIC 2026. #AAIC2026 #Alzheimers #BloodBiomarkers #Neurology

C2N continues to set a standard in innovation in Alzheimer’s disease diagnostics through numerous presentations by esteemed researchers and clinicians at AAIC. 12 sessions and 15 posters will offer novel insights relating to the Precivity™ blood tests. These presentations/posters include: Tuesday, July 14 8:02 – 8:09 am Racial and Ethnic Differences in %p-tau217 Associations with Cognitive Performance and Amyloid PET in Preclinical AD Location: N11B 8:16 – 8:23 am Broad Modulation of Core Tau Biomarkers, including p-tau205, Following Lecanemab Treatment Supports Disease Modification Beyond Amyloid Location: S11 8:23 – 8:30 am Consistently High Performance of Alzheimer's Disease Blood Test Across 12 Documented Comorbidities Location: N11B 9:26 – 9:38 am Effects of Alzheimer’s disease blood-based biomarkers on diagnosis and clinical management in secondary and primary care Location: ICC Auditorium 4:15 – 5:45 pm Developing topics Session - Real-World Validation of Alzheimer's Disease Blood Tests from Community to Primary Care Settings: Updates on SEABIRD and SUNBIRD Location: George V 1/2 5:02 – 5:17 pm Participant Characteristics and Alzheimer’s Disease Diagnostic Test Results in the Primary Care and Subspecialty Settings: Updates on SUNBIRD Location: GeorgeV 1/2 Posters (Exhibit Hall) Tuesday, July 14 #0333 ApoE E4 Attenuates the Association Between Plasma P-tau217 and Amyloid Pathology in Alzheimer’s Disease #0353 Discordance Between Plasma p-tau217 and PET Imaging as A Prognostic Marker in Alzheimer’s Disease #0447 Plasma Biomarkers Are Associated with Lower Memory index Scores and Recent Cognitive Decline #AAIC #AAIC26 #AAIC2026

C2N Diagnostics, LLC, a pioneer in advanced brain health diagnostics, is adding to its evidence-based legacy at the Alzheimer’s Association International Conference 2026 in London, July 12-15. Presentation by C2N CEO, Joel Braunstein, MD on Tuesday, July 14. 8:23 – 8:30 am Consistently High Performance of Alzheimer’s Disease Blood Test Across 12 Documented Comorbidities Location: N11B 10:30 – 11:00 am Product Theater Transforming Alzheimer’s Disease Diagnostics with Precision Medicine Location: Product Theater Stage #2 #AAIC #AAIC26 #AAIC2026

C2N Diagnostics, LLC, a pioneer in advanced brain health diagnostics, is adding to its evidence-based legacy at the Alzheimer’s Association International Conference 2026 in London, July 12-15. C2N continues to set a standard in innovation in Alzheimer’s disease diagnostics through numerous presentations by esteemed researchers and clinicians at AAIC. Please join us in London and be among the first to learn about exciting new data for the Precivity® line of blood tests. Please come visit our team at C2N Booth #431. Schedule a meeting at https://lnkd.in/eWthvw7C All sessions and posters will be held at the ExCel Conference Center in London. 12 sessions and 15 posters will offer novel insights relating to the Precivity™ blood tests. These presentations/posters include: Monday, July 13 9:12 – 9:22 am Etalanetug Reduces Tau Tangle Specific Plasma E-MTBR-tau243 in DIAD While increasing Plasma p-tau and t-tau in Healthy and DIAD* (*Work done in the laboratory of Dr. Bateman, Washington University, St. Louis.) Location: GeorgeV 1/2 9:52 – 10:02 am Baseline Imaging Characteristics of Participants in A Phase 2 Trial of Etalanetug and Concurrent Lecanemab Location: GeorgeV 1/2 11:00 – 12:15 pm Eligibility for Anti-Amyloid Immunotherapy: Amyloid Biomarkers in the Real World Location: S9 Posters (Exhibit Hall) Monday, July 13 #0081 Design of A Phase 2a Trial Of LRRK2 Inhibitor HT-4253 In Pre-symptomatic APOE4 Carriers Identified Via Population-scale Genomics in The UAE #0441 CSF eMTBR-tau243 – A candidate biomarker for diagnosis and disease staging in Alzheimer’s Disease #0474 Comparison of Automated Lumipulse and C2N Plasma Phospho-tau217 Assays in Relation to Amyloid-PET in individuals with Down Syndrome #0475 Clinical and Analytical Validation of CSF and Plasma eMTBR-tau243 Assays for Research Use Stop by poster #0475 to learn more about eMTBR-tau243 assay for Tau pathology from C2N staff. #0482 SANDBOX: NHS-embedded Ai Platform for Multimodal Biomarkers and Scalable Blood Sampling in Dementia